Wenqing Jia,Xiaonan Shen,Zichao Guo et al.
Wenqing Jia et al.
Introduction: Colorectal cancer (CRC) is the second most lethal malignancy worldwide. Immune checkpoint inhibitors (ICIs) benefit only 15% of patients with mismatch repair-deficient/microsatellite instability (dMMR/MSI) C...
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy [0.03%]
新型抗APRIL药物Sibiprenlimab治疗IgA肾病的研究进展
Sheila A Doggrell
Sheila A Doggrell
Introduction: Immunoglobulin A (IgA) nephropathy is a common immune-mediated kidney disease leading to high blood pressure and may progress to kidney failure. None of the present treatments are disease-modifying or prolon...
Rini Patadia,Thomas B Casale,John Fowler et al.
Rini Patadia et al.
Introduction: Asthma encompasses a spectrum of phenotypes often categorized into two groups- type 2 high (T2 high) and type 2 low (T2 low). T2 high includes atopic and eosinophilic presentations whereas T2 low is non-atop...
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa [0.03%]
secukinumab治疗中至重度汗腺炎的评估研究
Dimitra Stergianou,Theodora Kanni,Christina Damoulari et al.
Dimitra Stergianou et al.
Introduction: Until recently, biological therapy for hidradenitis suppurativa was limited to anti-tumor necrosis factor (TNF) blockade with adalimumab (ADA). However, not all patients respond to treatment with ADA. This h...
Correction [0.03%]
改正
Published Erratum
Expert opinion on biological therapy. 2024 Apr;24(4):313. DOI:10.1080/14712598.2024.2338643 2024
ZhiCheng Wang,XiaoMan Chen,Liang Yan et al.
ZhiCheng Wang et al.
Introduction: Antimicrobial peptides (AMPs) are small-molecule peptides with a unique antimicrobial mechanism. Other notable biological activities of AMPs, including anti-inflammatory, angiogenesis, and bone formation eff...
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk [0.03%]
生物制剂对降低银屑病心血管风险有效性的研究
Sara Boskovic,Silvia Borriello,Fabrizio D&#x;Ascenzo et al.
Sara Boskovic et al.
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies [0.03%]
低危骨髓增生异常综合征的Luspatercept：治疗策略的范式转变
Matteo Molica,Marco Rossi
Matteo Molica
Introduction: In patients with myelodysplastic syndromes (MDS), anemia is prevalent affecting 80%-85% of low-risk (LR-MDS) patients, with 40% eventually requiring red blood cell (RBC) transfusions. Except forlenalidomide,...
Ashish Sharma,Nilesh Kumar,Nikulaa Parachuri et al.
Ashish Sharma et al.
Introduction: Faricimab is a bispecific antibody that acts to reduce neoangiogenesis in exudative retinal vascular disorders. It is approved for use in neovascular age-related macular degeneration and diabetic macular ede...
IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents [0.03%]
双特异性的IgG-VHH融合抗体：作为药物的挑战与机遇
Andreas V Madsen,Peter Kristensen,Steffen Goletz
Andreas V Madsen